Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fluckiger

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Cell Death & Disease|June 21, 2019
Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1β secretion in 5-fluorouracil-treated MDSC: implication in cancer treatmentAdélie Dumont, Charlotte de Rosny, Trinh-Le-Vi Kieu, et al.
Science Translational Medicine|August 5, 2011
A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaquesPierre Garrone, Anne-Catherine Fluckiger, Philippe E Mangeot, et al.
American Journal of Hypertension|November 29, 2001
The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE studyJ D Lefrandt, J Heitmann, K Sevre, et al.
Oncoimmunology|September 16, 2020
Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitorsRomain Daillère, Bertrand Routy, Anne-Gaëlle Goubet, et al.
Oncoimmunology|December 8, 2018
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancerAlexandre Ivagnès, Meriem Messaoudene, Gautier Stoll, et al.
JCI Insight|December 15, 2020
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockadeGladys Ferrere, Maryam Tidjani Alou, Peng Liu, et al.
Cell Death and Differentiation|May 12, 2021
Multifaceted modes of action of the anticancer probiotic Enterococcus hiraeAnne-Gaëlle Goubet, Richard Wheeler, Aurélie Fluckiger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variantsM Messaoudene, T P Mourikis, J Michels, et al.
Nature Medicine|May 27, 2020
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancerMaria Paula Roberti, Satoru Yonekura, Connie P M Duong, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsBertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Cell Death & Disease|June 21, 2019
Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1β secretion in 5-fluorouracil-treated MDSC: implication in cancer treatmentAdélie Dumont, Charlotte de Rosny, Trinh-Le-Vi Kieu, et al.
Science Translational Medicine|August 5, 2011
A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaquesPierre Garrone, Anne-Catherine Fluckiger, Philippe E Mangeot, et al.
American Journal of Hypertension|November 29, 2001
The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE studyJ D Lefrandt, J Heitmann, K Sevre, et al.
Oncoimmunology|September 16, 2020
Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitorsRomain Daillère, Bertrand Routy, Anne-Gaëlle Goubet, et al.
Oncoimmunology|December 8, 2018
TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancerAlexandre Ivagnès, Meriem Messaoudene, Gautier Stoll, et al.
JCI Insight|December 15, 2020
Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockadeGladys Ferrere, Maryam Tidjani Alou, Peng Liu, et al.
Cell Death and Differentiation|May 12, 2021
Multifaceted modes of action of the anticancer probiotic Enterococcus hiraeAnne-Gaëlle Goubet, Richard Wheeler, Aurélie Fluckiger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2019
T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variantsM Messaoudene, T P Mourikis, J Michels, et al.
Nature Medicine|May 27, 2020
Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancerMaria Paula Roberti, Satoru Yonekura, Connie P M Duong, et al.
Science (New York, N.Y.)|November 4, 2017
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumorsBertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, et al.
Pageof 14